HC Wainwright Reiterates Buy Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $27.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 60.62% from the stock’s current price.

EOLS has been the topic of several other reports. Barclays increased their price target on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Needham & Company LLC reiterated a “buy” rating and set a $22.00 target price on shares of Evolus in a research note on Friday, September 13th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Evolus in a report on Monday, September 16th.

Evolus Stock Up 1.9 %

EOLS stock opened at $16.81 on Thursday. Evolus has a 1-year low of $7.74 and a 1-year high of $17.82. The business’s 50 day simple moving average is $16.29 and its 200 day simple moving average is $13.83. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. The firm has a market capitalization of $1.06 billion, a PE ratio of -18.47 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The business had revenue of $61.09 million for the quarter, compared to analysts’ expectations of $62.81 million. As a group, research analysts anticipate that Evolus will post -0.64 EPS for the current year.

Insider Buying and Selling at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at $2,224,559.96. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the completion of the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Institutional investors and hedge funds have recently made changes to their positions in the company. Quest Partners LLC bought a new position in Evolus in the second quarter valued at approximately $43,000. Quarry LP bought a new position in shares of Evolus in the 2nd quarter valued at $54,000. Profund Advisors LLC acquired a new position in shares of Evolus during the 2nd quarter worth $130,000. Arizona State Retirement System raised its holdings in shares of Evolus by 9.4% during the 2nd quarter. Arizona State Retirement System now owns 14,603 shares of the company’s stock worth $158,000 after buying an additional 1,253 shares in the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Evolus by 9.9% during the 1st quarter. ProShare Advisors LLC now owns 11,542 shares of the company’s stock worth $162,000 after buying an additional 1,035 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.